Probiodrug to present at Alzheimer's and Parkinson's Diseases Congress
New results of a double pronged-approach to target the neurotoxic amyloid beta species pGlu-Abeta, and an evaluation of new biomarkers in cerebrospinal fluid (CSF) from AD patients
HALLE (SAALE), Germany, 28 March 2017 - Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's disease (AD), announced today that three updates on the advancement of its product candidates and the results of a Biomarker research collaboration will be presented at the 13 th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD TM 2017). The conference will take place in Vienna, Austria from 29 th March to 2 nd April 2017.
Dr. Inge Lues, Chief Development Officer of Probiodrug commented: "We are excited about the progress that has been made over the course of last year and the value added to our programs, and look forward to presenting the updates at the conference."
| Program | Presentations and Timing |
| QC- enzyme/CSF Biomarker Collaborator: VUmed Center Amsterdam, The Netherlands | Cerebrospinal fluid glutaminyl cyclase (QC) activity correlates with Alzheimer's disease biomarkers and inflammation molecules in AD patients Poster - 29th March - In CSF from AD patients high correlation of QC activity with AD related biomarkers and inflammatory molecules were found |
| QC-Inhibitor PQ912 Collaborator: Fraunhofer Institute, Halle (Saale), Germany | Glutaminyl cyclase inhibition by PQ912 in transgenic mice with Alzheimer-like pathology-translation to clinics Poster - 31st March - Based on PKPD analysis in animal studies, a 50% inhibition of QC activity in the brain leads to a robust effect - an important translational guidance for therapeutic dosing in clinical studies |
| Anti-pGlu-Abeta MAB/QC-I Collaborator: Harvard, BWH, Boston, USA | Murine anti-pyroglutamate-3 Abeta MAB, 07/2a, spares cognition, reduces plaques, and, in combination with glutaminyl cyclase inhibitor PQ912 further improves efficacy Oral Presentation - 29th March / 11:45-12:00 -Selective targeting of pGlu-Abeta with an IgG2a in tg mice is effective in lowering plaque pathology and improving cognition a combination of a QC-inhibitor and a pGlu-Abeta specific antibody showed superior efficacy |
###
For more information, please contact:
Probiodrug Dr Konrad Glund, CEO Email: contact@probiodrug.de
Hume Brophy Conor Griffin, Alexia Faure, Alexander Protsenko Tel: +44 (0) 20 7862 6381 Email: probiodrug@humebrophy.com
The Trout Group Tricia Truehart Tel: +1 (646) 378-2953 Email: ttruehart@troutgroup.com
MC Services AG Anne Hennecke, Caroline Bergmann Tel: +49 (0) 211 529 252 20 Email: probiodrug@mc-services.eu
Notes to Editors: About Probiodrug AG Headquartered in Halle (Saale), Germany, Probiodrug AG (Euronext Amsterdam: PBD) is a biopharmaceutical company focused on the development of new therapeutic products for the treatment of Alzheimer's disease.
Founded in 1997, the company successfully developed a novel therapeutic concept for diabetes - the DP4 inhibitors - which provided the basis for a novel class of antidiabetics - the gliptins. Its core capabilities are based on its long-standing expertise in the elucidation of the structure and function of enzymes involved in the modification of proteins and peptides, which play a central role in pathological conditions.
Today Probiodrug's aim is to become a leading company in the development of Alzheimer's disease treatments and to thereby provide a better life for Alzheimer's disease patients. It has identified a new therapeutic concept linked to disease initiation and progression. The development approaches are targeting pyroglutamate-Abeta (pGlu-Abeta) as a therapeutic strategy to fight Alzheimer's disease. The Company has medical use and composition of matter patents related to the inhibition of Glutaminyl Cyclase (QC) and anti-pGlu-Abeta- specific monoclonal antibodies, providing it, in the Company's view, with a leading position in this field of research.
Probiodrug's lead product candidate, PQ912, is a highly specific and potent inhibitor of Glutaminyl Cyclase (QC), which has shown therapeutic effects in Alzheimer's animal models. PQ912 is currently in a Phase 2a study, the SAPHIR trial. In a preceding Phase 1 study with healthy young and elderly volunteers, PQ912 has shown to be safe and well tolerated and also revealed high QC-inhibition.
About Alzheimer's disease Alzheimer's disease is a neurological disorder, which is the most common form of dementia, and ultimately leads to death. Because Alzheimer's disease cannot be cured and is degenerative, the affected patients must increasingly rely on others for assistance. Today, 47 million people live with dementia worldwide, and this number is projected to treble to more than 131 million by 2050, as populations age. Dementia also has a huge economic impact. Alzheimer's has an estimated, global societal cost of US$ 818 billion, and it will become a trillion dollar disease by 2018. (World Alzheimer Report 2016).
Forward Looking Statements Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Probiodrug AG as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.
